{{DISPLAYTITLE:''meta''-Chlorophenylpiperazine}}
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 457790176
| drug_name = ''meta''-Chlorophenylpiperazine
| IUPAC_name = 1-(3-chlorophenyl)piperazine
| image = MCPP.svg
| width = 185px
| image2 = MCPP-3D-vdW.png
| width2 = 165px
<!--Clinical data-->
| tradename = 
| legal_DE = Anlage II
| routes_of_administration = Oral, intranasal, rectal
<!--Pharmacokinetic data-->
| bioavailability = 
| metabolism = Hepatic
| elimination_half-life = 2–6 hours
| excretion = Renal
<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 6640-24-0
| ATC_prefix = None
| ATC_suffix = 
| PubChem = 1355
| IUPHAR_ligand = 142
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 1314
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = REY0CNO998
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 10588
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 478
<!--Chemical data-->
| C=10 | H=13 | Cl=1 | N=2
| molecular_weight = 196.676 g/mol
| SMILES = Clc1cc(ccc1)N2CCNCC2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C10H13ClN2/c11-9-2-1-3-10(8-9)13-6-4-12-5-7-13/h1-3,8,12H,4-7H2
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = VHFVKMTVMIZMIK-UHFFFAOYSA-N
}}

'''''meta''-Chlorophenylpiperazine''' ('''mCPP''') is a [[psychoactive drug]] of the [[phenylpiperazine]] class. It was initially developed in the late-1970s and used in [[scientific research]] before being sold as a [[designer drug]] in the mid-2000s.<ref name="pmid16318952">{{cite journal |vauthors=Bossong MG, Van Dijk JP, Niesink RJ | title = Methylone and mCPP, two new drugs of abuse? | journal = [[Addiction Biology]] | volume = 10 | issue = 4 | pages = 321–3 |date=December 2005 | pmid = 16318952 | doi = 10.1080/13556210500350794 | url = http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=1355-6215&date=2005&volume=10&issue=4&spage=321}}</ref><ref name="pmid17348609">{{cite journal |vauthors=Lecompte Y, Evrard I, Arditti J | title = [Metachlorophenylpiperazine (mCPP): a new designer drug] | language = French | journal = Thérapie | volume = 61 | issue = 6 | pages = 523–30 | year = 2006 | pmid = 17348609 | doi = 10.2515/therapie:2006093| url = }}</ref> It has been detected in pills touted as legal alternatives to illicit [[stimulant]]s in [[New Zealand]] and pills sold as "[[MDMA|ecstasy]]" in [[Europe]] and the [[United States]].<ref name="pmid19304863">{{cite journal |vauthors=Bossong M, Brunt T, Van Dijk J, etal | title = mCPP: an undesired addition to the ecstasy market | journal = Journal of Psychopharmacology (Oxford, England) | volume = 24| issue = 9| pages = 1395–401|date=March 2009 | pmid = 19304863 | doi = 10.1177/0269881109102541 | url = http://jop.sagepub.com/cgi/pmidlookup?view=long&pmid=19304863}}</ref><ref name="pmid19804461">{{cite journal |vauthors=Vogels N, Brunt TM, Rigter S, van Dijk P, Vervaeke H, Niesink RJ | title = Content of ecstasy in the Netherlands: 1993-2008 | journal = Addiction (Abingdon, England) | volume = 104 | issue = 12 | pages = 2057–66 |date=December 2009 | pmid = 19804461 | doi = 10.1111/j.1360-0443.2009.02707.x | url = http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0965-2140&date=2009&volume=104&issue=12&spage=2057}}</ref>

Despite its advertisement as a [[recreational drug|recreational substance]], mCPP is actually generally considered to be an unpleasant experience and is not desired by drug users.<ref name="pmid19304863"/> It lacks any [[reinforcing]] or [[hallucinogen]]ic effects,<ref name="pmid14563541">{{cite journal |vauthors=Tancer M, Johanson CE | title = Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP | journal = Drug and Alcohol Dependence | volume = 72 | issue = 1 | pages = 33–44 |date=October 2003 | pmid = 14563541 | doi = 10.1016/S0376-8716(03)00172-8| url = http://linkinghub.elsevier.com/retrieve/pii/S0376871603001728}}</ref><ref name="pmid9933142" /> produces [[dysphoric]], [[depression (mood)|depressive]], and [[anxiogenic]] effects in rodents and humans,<ref name="pmid19269287">{{cite journal |vauthors=Rajkumar R, Pandey DK, Mahesh R, Radha R | title = 1-(m-Chlorophenyl)piperazine induces depressogenic-like behaviour in rodents by stimulating the neuronal 5-HT(2A) receptors: proposal of a modified rodent antidepressant assay | journal = European Journal of Pharmacology | volume = 608 | issue = 1-3 | pages = 32–41 |date=April 2009 | pmid = 19269287 | doi = 10.1016/j.ejphar.2009.02.041 | url = http://linkinghub.elsevier.com/retrieve/pii/S0014-2999(09)00198-8}}</ref><ref name="pmid2767117">{{cite journal |vauthors=Kennett GA, Whitton P, Shah K, Curzon G | title = Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists | journal = European Journal of Pharmacology | volume = 164 | issue = 3 | pages = 445–54 |date=May 1989 | pmid = 2767117 | doi = 10.1016/0014-2999(89)90252-5| url = }}</ref> and can induce [[panic attack]]s in individuals susceptible to them.<ref name="pmid1756202">{{cite journal |vauthors=Klein E, Zohar J, Geraci MF, Murphy DL, Uhde TW | title = Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects | journal = Biological Psychiatry | volume = 30 | issue = 10 | pages = 973–84 |date=November 1991 | pmid = 1756202 | doi = 10.1016/0006-3223(91)90119-7| url = }}</ref><ref name="pmid3110824">{{cite journal |vauthors=Charney DS, Woods SW, Goodman WK, Heninger GR | title = Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects | journal = Psychopharmacology | volume = 92 | issue = 1 | pages = 14–24 | year = 1987 | pmid = 3110824 | doi = 10.1007/bf00215473| url = }}</ref><ref name="pmid17481859">{{cite journal |vauthors=Van Veen JF, Van der Wee NJ, Fiselier J, Van Vliet IM, Westenberg HG | title = Behavioural effects of rapid intravenous administration of meta-chlorophenylpiperazine (m-CPP) in patients with generalized social anxiety disorder, panic disorder and healthy controls | journal = European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology | volume = 17 | issue = 10 | pages = 637–42 |date=October 2007 | pmid = 17481859 | doi = 10.1016/j.euroneuro.2007.03.005 | url = http://linkinghub.elsevier.com/retrieve/pii/S0924-977X(07)00082-X}}</ref><ref name="pmid15336303">{{cite journal |vauthors=van der Wee NJ, Fiselier J, van Megen HJ, Westenberg HG | title = Behavioural effects of rapid intravenous administration of meta-chlorophenylpiperazine in patients with panic disorder and controls | journal = European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology | volume = 14 | issue = 5 | pages = 413–7 |date=October 2004 | pmid = 15336303 | doi = 10.1016/j.euroneuro.2004.01.001 | url = http://linkinghub.elsevier.com/retrieve/pii/S0924977X0400015X}}</ref> It also worsens [[obsessive-compulsive disorder|obsessive–compulsive]] symptoms in people with the disorder.<ref name="pmid1728249">{{cite journal |vauthors=Hollander E, DeCaria CM, Nitescu A, etal | title = Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers | journal = Archives of General Psychiatry | volume = 49 | issue = 1 | pages = 21–8 |date=January 1992 | pmid = 1728249 | doi = 10.1001/archpsyc.1992.01820010021003| url = http://archpsyc.ama-assn.org/cgi/pmidlookup?view=long&pmid=1728249}}</ref><ref name="pmid9676822">{{cite journal |vauthors=Broocks A, Pigott TA, Hill JL, etal | title = Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results | journal = Psychiatry Research | volume = 79 | issue = 1 | pages = 11–20 |date=June 1998 | pmid = 9676822 | doi = 10.1016/S0165-1781(98)00029-8| url = http://linkinghub.elsevier.com/retrieve/pii/S0165178198000298}}</ref><ref name="pmid2018816">{{cite journal |vauthors=Pigott TA, Zohar J, Hill JL, etal | title = Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder | journal = Biological Psychiatry | volume = 29 | issue = 5 | pages = 418–26 |date=March 1991 | pmid = 2018816 | doi = 10.1016/0006-3223(91)90264-M| url = }}</ref>

mCPP is known to induce [[headache]]s in humans and has been used for testing potential [[antimigraine]] medications.<ref name="Leone">{{cite journal | last = Leone | first = M |author2=A Attanasio |author3=D Croci |author4=G Filippini |author5=D D'Amico |author6=L Grazzi |author7=A Nespolo |author8=G Bussone | title = The serotonergic agent m-chlorophenylpiperazine induces migraine attacks: A controlled study | journal = Neurology | volume = 55 | issue = 1 | pages = 136–139 | date = July 12, 2000 | url = | doi = 10.1212/wnl.55.1.136| pmid = 10891925}}</ref><ref name="Martin et al.">Martin RS & Martin GR. Investigations into migraine pathogenesis: time course for effects of m-CPP, BW723C86 or glyceryl trinitrate on appearance of Fos-like immunoreactivity in rat trigeminal nucleus caudalis (TNC). Cephalalgia 2001; 21:46–52. London. {{ISSN|0333-1024}}</ref><ref name="Petkov et al.">Petkov VD, Belcheva S, Konstantinova E. Anxiolytic effects of dotarizine, a possible antimigraine drug. Methods Find Exp Clin Pharmacol. 1995 Dec;17(10):659-68.</ref> It has potent [[anorectic]] effects and has encouraged the development of selective [[5-HT2C receptor|5-HT<sub>2C</sub> receptor]] [[agonist]]s for the treatment of [[obesity]] as well.<ref name="pmid2906446">{{cite journal |vauthors=Kennett GA, Curzon G | title = Evidence that hypophagia induced by mCPP and TFMPP requires 5-HT1C and 5-HT1B receptors; hypophagia induced by RU 24969 only requires 5-HT1B receptors | journal = Psychopharmacology | volume = 96 | issue = 1 | pages = 93–100 | year = 1988 | pmid = 2906446 | doi = 10.1007/BF02431539| url = }}</ref><ref name="pmid9361339">{{cite journal |vauthors=Sargent PA, Sharpley AL, Williams C, Goodall EM, Cowen PJ | title = 5-HT2C receptor activation decreases appetite and body weight in obese subjects | journal = Psychopharmacology | volume = 133 | issue = 3 | pages = 309–12 |date=October 1997 | pmid = 9361339 | doi = 10.1007/s002130050407| url = http://link.springer.de/link/service/journals/00213/bibs/7133003/71330309.htm}}</ref><ref name="pmid15719229">{{cite journal |vauthors=Hayashi A, Suzuki M, Sasamata M, Miyata K | title = Agonist diversity in 5-HT(2C) receptor-mediated weight control in rats | journal = Psychopharmacology | volume = 178 | issue = 2-3 | pages = 241–9 |date=March 2005 | pmid = 15719229 | doi = 10.1007/s00213-004-2019-z}}</ref><ref name="pmid17209663">{{cite journal |vauthors=Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE | title = Serotonergic drugs : effects on appetite expression and use for the treatment of obesity | journal = Drugs | volume = 67 | issue = 1 | pages = 27–55 | year = 2007 | pmid = 17209663 | doi = 10.2165/00003495-200767010-00004| url = http://content.wkhealth.com/linkback/openurl?issn=0012-6667&volume=67&issue=1&spage=27}}</ref>

{{TOC limit|3}}

==Pharmacology==

===Pharmacodynamics===
{| class="wikitable floatleft" style="font-size:small;"
|+ mCPP<ref name="PDSP">{{cite web | title = PDSP K<sub>i</sub> Database | work = Psychoactive Drug Screening Program (PDSP) | author1 = Roth, BL | author2 = Driscol, J | publisher = University of North Carolina at Chapel Hill and the United States National Institute of Mental Health || format = HTML | accessdate = 14 August 2017 | url = https://pdsp.unc.edu/databases/pdsp.php?knowID=0&kiKey=&receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testDDRadio=testDDRadio&testLigandDD=1827&testLigand=&refDDRadio=refDDRadio&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query}}</ref>
|-
! Site !! K<sub>i</sub> (nM) !! Species !! Refs
|-
| '''{{abbrlink|SERT|Serotonin transporter}}''' || '''202–432''' || '''Human''' || <ref name="pmid9400006">{{cite journal | vauthors = Owens MJ, Morgan WN, Plott SJ, Nemeroff CB | title = Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites | journal = J. Pharmacol. Exp. Ther. | volume = 283 | issue = 3 | pages = 1305–22 | year = 1997 | pmid = 9400006 | doi = | url = }}</ref>
|-
| {{abbrlink|NET|Norepinephrine transporter}} || 1,940–4,360 || Human || <ref name="pmid9400006" />
|-
| {{abbrlink|DAT|Dopamine transporter}} || {{abbr|ND|No data}} || {{abbr|ND|No data}} || {{abbr|ND|No data}}
|-
| '''[[5-HT1A receptor|5-HT<sub>1A</sub>]]''' || '''44–400''' || Human || <ref name="PDSP" /><ref name="pmid2537663">{{cite journal | vauthors = Hamik A, Peroutka SJ | title = 1-(m-chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain | journal = Biol. Psychiatry | volume = 25 | issue = 5 | pages = 569–75 | year = 1989 | pmid = 2537663 | doi = | url = }}</ref>
|-
| '''[[5-HT1B receptor|5-HT<sub>1B</sub>]]''' || '''89–501''' || Human || <ref name="PDSP" /><ref name="pmid7984267">{{cite journal | vauthors = Boess FG, Martin IL | title = Molecular biology of 5-HT receptors | journal = Neuropharmacology | volume = 33 | issue = 3-4 | pages = 275–317 | year = 1994 | pmid = 7984267 | doi = | url = }}</ref>
|-
| '''[[5-HT1D receptor|5-HT<sub>1D</sub>]]''' || '''210–1,300''' || '''Human''' || <ref name="pmid2537663" /><ref name="pmid1652050">{{cite journal | vauthors = Hamblin MW, Metcalf MA | title = Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor | journal = Mol. Pharmacol. | volume = 40 | issue = 2 | pages = 143–8 | year = 1991 | pmid = 1652050 | doi = | url = }}</ref>
|-
| [[5-HT1E receptor|5-HT<sub>1E</sub>]] || {{abbr|ND|No data}} || {{abbr|ND|No data}} || {{abbr|ND|No data}}
|-
| [[5-HT1F receptor|5-HT<sub>1F</sub>]] || {{abbr|ND|No data}} || {{abbr|ND|No data}} || {{abbr|ND|No data}}
|-
| '''[[5-HT2A receptor|5-HT<sub>2A</sub>]]''' || '''32–398''' || '''Human''' || <ref name="PDSP" /><ref name="pmid9933142" /><ref name="pmid2537663" /><ref name="pmid7582481">{{cite journal | vauthors = Bonhaus DW, Bach C, DeSouza A, Salazar FH, Matsuoka BD, Zuppan P, Chan HW, Eglen RM | title = The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors | journal = Br. J. Pharmacol. | volume = 115 | issue = 4 | pages = 622–8 | year = 1995 | pmid = 7582481 | pmc = 1908489 | doi = | url = }}</ref>
|-
| '''[[5-HT2B receptor|5-HT<sub>2B</sub>]]''' || '''3.2–63''' || '''Human''' || <ref name="PDSP" /><ref name="pmid11104741">{{cite journal | vauthors = Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL | title = Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications | journal = Circulation | volume = 102 | issue = 23 | pages = 2836–41 | year = 2000 | pmid = 11104741 | doi = | url = }}</ref><ref name="pmid10498829">{{cite journal | vauthors = Porter RH, Benwell KR, Lamb H, Malcolm CS, Allen NH, Revell DF, Adams DR, Sheardown MJ | title = Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells | journal = Br. J. Pharmacol. | volume = 128 | issue = 1 | pages = 13–20 | year = 1999 | pmid = 10498829 | pmc = 1571597 | doi = 10.1038/sj.bjp.0702751 | url = }}</ref>
|-
| '''[[5-HT2C receptor|5-HT<sub>2C</sub>]]''' || '''3.4–251''' || Human || <ref name="PDSP" /><ref name="pmid9933142" /><ref name="pmid7582481" /><ref name="pmid15081042">{{cite journal | vauthors = Bentley JM, Adams DR, Bebbington D, Benwell KR, Bickerdike MJ, Davidson JE, Dawson CE, Dourish CT, Duncton MA, Gaur S, George AR, Giles PR, Hamlyn RJ, Kennett GA, Knight AR, Malcolm CS, Mansell HL, Misra A, Monck NJ, Pratt RM, Quirk K, Roffey JR, Vickers SP, Cliffe IA | title = Indoline derivatives as 5-HT(2C) receptor agonists | journal = Bioorg. Med. Chem. Lett. | volume = 14 | issue = 9 | pages = 2367–70 | year = 2004 | pmid = 15081042 | doi = 10.1016/j.bmcl.2003.05.001 | url = }}</ref>
|-
| '''[[5-HT3 receptor|5-HT<sub>3</sub>]]''' || '''427''' || '''Human''' || <ref name="PDSP" />
|-
| [[5-HT4 receptor|5-HT<sub>4</sub>]] || {{abbr|ND|No data}} || {{abbr|ND|No data}} || {{abbr|ND|No data}}
|-
| [[5-HT5A receptor|5-HT<sub>5A</sub>]]&nbsp;<!--Spacing--> || 1,354 || Human || <ref name="PDSP" />
|-
| [[5-HT6 receptor|5-HT<sub>6</sub>]] || 1,748 || Human || <ref name="PDSP" />
|-
| '''[[5-HT7 receptor|5-HT<sub>7</sub>]]''' || '''163''' || '''Human''' || <ref name="PDSP" />
|-
| '''[[Alpha-1 adrenergic receptor|α<sub>1</sub>]]''' || '''97–2,900''' || '''Human''' || <ref name="pmid9400006" /><ref name="pmid2537663" />
|-
| &nbsp;&nbsp;[[Alpha-1A adrenergic receptor|α<sub>1A</sub>]] || 1,386 || Human || <ref name="PDSP" />
|-
| &nbsp;&nbsp;[[Alpha-1B adrenergic receptor|α<sub>1B</sub>]] || 915 || Human || <ref name="PDSP" />
|-
| &nbsp;&nbsp;[[Alpha-1D adrenergic receptor|α<sub>1D</sub>]] || {{abbr|ND|No data}} || {{abbr|ND|No data}} || {{abbr|ND|No data}}
|-
| '''[[Alpha-2 adrenergic receptor|α<sub>2</sub>]]''' || '''112–570''' || '''Human''' || <ref name="pmid9400006" /><ref name="pmid2537663" />
|-
| '''&nbsp;&nbsp;[[Alpha-2A adrenergic receptor|α<sub>2A</sub>]]''' || '''145''' || Human || <ref name="PDSP" />
|-
| '''&nbsp;&nbsp;[[Alpha-2B adrenergic receptor|α<sub>2B</sub>]]''' || '''106''' || Human || <ref name="PDSP" />
|-
| '''&nbsp;&nbsp;[[Alpha-2C adrenergic receptor|α<sub>2C</sub>]]''' || '''124''' || Human || <ref name="PDSP" />
|-
| [[Beta adrenergic receptor|β]] || 2,500 || Human || <ref name="pmid2537663" />
|-
| &nbsp;&nbsp;[[Beta-1 adrenergic receptor|β<sub>1</sub>]] || 2,359 || Human || <ref name="PDSP" />
|-
| &nbsp;&nbsp;[[Beta-2 adrenergic receptor|β<sub>2</sub>]] || 3,474 || Human || <ref name="PDSP" />
|-
| [[Dopamine D1 receptor|D<sub>1</sub>]] || 7,000 || Human || <ref name="pmid2537663" />
|-
| [[Dopamine D2 receptor|D<sub>2</sub>]] || >10,000 || Human || <ref name="pmid2537663" />
|-
| [[Dopamine D3 receptor|D<sub>3</sub>]] || >10,000 || Rat || <ref name="PDSP" />
|-
| [[Dopamine D4 receptor|D<sub>4</sub>]] || {{abbr|ND|No data}} || {{abbr|ND|No data}} || {{abbr|ND|No data}}
|-
| [[Dopamine D5 receptor|D<sub>5</sub>]] || >10,000 || Human || <ref name="PDSP" />
|-
| '''[[Histamine H1 receptor|H<sub>1</sub>]]''' || '''326''' || '''Human''' || <ref name="PDSP" />
|-
| [[Muscarinic acetylcholine receptor|mAChRs]] || >10,000 || Human || <ref name="pmid2537663" />
|-
| {{abbrlink|nAChRs|Nicotinic acetylcholine receptors}} || >10,000 || Human || <ref name="PDSP" />
|-
| [[Sigma-1 receptor|σ<sub>1</sub>]] || {{abbr|ND|No data}} || {{abbr|ND|No data}} || {{abbr|ND|No data}}
|-
| [[Sigma-2 receptor|σ<sub>2</sub>]] || 8,350 || Rat || <ref name="PDSP" />
|-
| [[Imidazoline receptor|I<sub>1</sub>]] || 759 || Rat || <ref name="PDSP" />
|-
| {{abbrlink|VDCC|Voltage-dependent calcium channel}} || 6,043 || Rat || <ref name="PDSP" />
|- class="sortbottom"
| colspan="4" style="width: 1px;" | Values are K<sub>i</sub> (nM). The smaller the value, the more strongly the drug binds to the site.
|}

mCPP possesses significant [[affinity (pharmacology)|affinity]] for the [[5-HT1A receptor|5-HT<sub>1A</sub>]], [[5-HT1B receptor|5-HT<sub>1B</sub>]], [[5-HT1D receptor|5-HT<sub>1D</sub>]], [[5-HT2A receptor|5-HT<sub>2A</sub>]], [[5-HT2B receptor|5-HT<sub>2B</sub>]], [[5-HT2C receptor|5-HT<sub>2C</sub>]], [[5-HT3 receptor|5-HT<sub>3</sub>]], and [[5-HT7 receptor|5-HT<sub>7</sub> receptor]]s, as well as the [[serotonin transporter|SERT]].<ref name="PDSP" /> It also has some affinity for [[alpha-1 adrenergic|α<sub>1</sub>-adrenergic]], [[alpha-2 adrenergic|α<sub>2</sub>-adrenergic]], [[H1 receptor|H<sub>1</sub>]], [[Imidazoline receptor|I<sub>1</sub>]], and [[norepinephrine transporter|NET]].<ref name="PDSP" /><ref name="pmid7814826">{{cite journal |vauthors=Silverstone PH, Rue JE, Franklin M, etal | title = The effects of administration of mCPP on psychological, cognitive, cardiovascular, hormonal and MHPG measurements in human volunteers | journal = International Clinical Psychopharmacology | volume = 9 | issue = 3 | pages = 173–8 |date=September 1994 | pmid = 7814826 | doi = 10.1097/00004850-199409000-00005| url = }}</ref> It behaves as an [[agonist]] at most serotonin receptors.<ref name="pmid503247">{{cite journal |vauthors=Samanin R, Mennini T, Ferraris A, Bendotti C, Borsini F, Garattini S | title = Chlorophenylpiperazine: a central serotonin agonist causing powerful anorexia in rats | journal = Naunyn-Schmiedeberg's Archives of Pharmacology | volume = 308 | issue = 2 | pages = 159–63 |date=August 1979 | pmid = 503247 | doi = 10.1007/BF00499059| url = }}</ref><ref name="pmid15888508">{{cite journal |vauthors=Odagaki Y, Toyoshima R, Yamauchi T | title = Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding | journal = Journal of Psychopharmacology (Oxford, England) | volume = 19 | issue = 3 | pages = 235–41 |date=May 2005 | pmid = 15888508 | doi = 10.1177/0269881105051526 | url = http://jop.sagepub.com/cgi/pmidlookup?view=long&pmid=15888508}}</ref> mCPP has been shown to act not only as a [[serotonin reuptake inhibitor]] but as a [[serotonin releasing agent]] as well.<ref name="pmid6610423">{{cite journal |vauthors=Pettibone DJ, Williams M | title = Serotonin-releasing effects of substituted piperazines in vitro | journal = [[Biochemical Pharmacology (journal)|Biochemical Pharmacology]] | volume = 33 | issue = 9 | pages = 1531–5 |date=May 1984 | pmid = 6610423 | doi = 10.1016/0006-2952(84)90424-6| url = http://linkinghub.elsevier.com/retrieve/pii/0006-2952(84)90424-6}}</ref>

mCPP's strongest actions are at the 5-HT<sub>2B</sub> and 5-HT<sub>2C</sub> receptors and its discriminative cue is mediated primarily by 5-HT<sub>2C</sub>.<ref name="PDSP"/><ref name="pmid8082704">{{cite journal |vauthors=Callahan PM, Cunningham KA | title = Involvement of 5-HT2C receptors in mediating the discriminative stimulus properties of m-chlorophenylpiperazine (mCPP) | journal = European Journal of Pharmacology | volume = 257 | issue = 1-2 | pages = 27–38 |date=May 1994 | pmid = 8082704 | doi = 10.1016/0014-2999(94)90690-4| url = http://linkinghub.elsevier.com/retrieve/pii/0014-2999(94)90690-4}}</ref><ref name="pmid9683007">{{cite journal |vauthors=Gommans J, Hijzen TH, Maes RA, Olivier B | title = Discriminative stimulus properties of mCPP: evidence for a 5-HT2C receptor mode of action | journal = Psychopharmacology | volume = 137 | issue = 3 | pages = 292–302 |date=June 1998 | pmid = 9683007 | doi = 10.1007/s002130050622| url = http://link.springer.de/link/service/journals/00213/bibs/8137003/81370292.htm}}</ref> Its negative effects such as [[anxiety]], [[headache]]s, and [[anorexia (symptom)|appetite loss]] are likely mediated by its actions on the 5-HT<sub>2C</sub> receptor.<ref name="pmid2767117"/><ref name="pmid2906446"/><ref name="pmid3401632">{{cite journal |vauthors=Kennett GA, Curzon G | title = Evidence that mCPP may have behavioural effects mediated by central 5-HT1C receptors | journal = [[British Journal of Pharmacology]] | volume = 94 | issue = 1 | pages = 137–47 |date=May 1988 | pmid = 3401632 | pmc = 1853919 | doi = 10.1111/j.1476-5381.1988.tb11508.x| url = }}</ref> Other effects of mCPP include [[nausea]], [[hypoactivity]], and [[penile erection]], the latter two the result of increased 5-HT<sub>2C</sub> activity and the former likely via 5-HT<sub>3</sub> stimulation.<ref name="pmid2775468">{{cite journal |vauthors=Kłodzińska A, Jaros T, Chojnacka-Wójcik E, Maj J | title = Exploratory hypoactivity induced by m-trifluoromethylphenylpiperazine (TFMPP) and m-chlorophenylpiperazine (m-CPP) | journal = Journal of Neural Transmission. Parkinson's Disease and Dementia Section | volume = 1 | issue = 3 | pages = 207–18 | year = 1989 | pmid = 2775468 | doi = 10.1007/BF02248670| url = }}</ref><ref name="pmid7862925">{{cite journal |vauthors=Walsh AE, Smith KA, Oldman AD, Williams C, Goodall EM, Cowen PJ | title = m-Chlorophenylpiperazine decreases food intake in a test meal | journal = Psychopharmacology | volume = 116 | issue = 1 | pages = 120–2 |date=September 1994 | pmid = 7862925 | doi = 10.1007/BF02244883| url = }}</ref><ref name="pmid8001637">{{cite journal |vauthors=Stancampiano R, Melis MR, Argiolas A | title = Penile erection and yawning induced by 5-HT1C receptor agonists in male rats: relationship with dopaminergic and oxytocinergic transmission | journal = European Journal of Pharmacology | volume = 261 | issue = 1-2 | pages = 149–55 |date=August 1994 | pmid = 8001637 | doi = 10.1016/0014-2999(94)90313-1| url = http://linkinghub.elsevier.com/retrieve/pii/0014-2999(94)90313-1}}</ref>

In comparison studies, mCPP has approximately 10-fold [[binding selectivity|selectivity]] for the human 5-HT<sub>2C</sub> receptor over the human 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub> receptors (K<sub>i</sub> = 3.4&nbsp;nM vs. 32.1 and 28.8&nbsp;nM).<ref name="pmid9933142">{{cite journal | vauthors = Nelson DL, Lucaites VL, Wainscott DB, Glennon RA | title = Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors | journal = Naunyn Schmiedebergs Arch. Pharmacol. | volume = 359 | issue = 1 | pages = 1–6 | year = 1999 | pmid = 9933142 | doi = | url = }}</ref> It acts as a [[partial agonist]] of the human 5-HT<sub>2C</sub> receptor but as an [[receptor antagonist|antagonist]] of the human 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub> receptors.<ref name="pmid9933142" /><ref name="pmid8856697">{{cite journal | vauthors = Thomas DR, Gager TL, Holland V, Brown AM, Wood MD | title = m-Chlorophenylpiperazine (mCPP) is an antagonist at the cloned human 5-HT2B receptor | journal = Neuroreport | volume = 7 | issue = 9 | pages = 1457–60 | year = 1996 | pmid = 8856697 | doi = | url = }}</ref> In accordance with its lack of agonism towards the human 5-HT<sub>2A</sub> receptor, there are no reports that mCPP produces [[hallucinogen]]ic effects in humans.<ref name="pmid9933142" />

===Pharmacokinetics===
mCPP is [[metabolism|metabolized]] via the [[CYP2D6]] [[isoenzyme]] by [[hydroxylation]] to ''para''-hydroxy-mCPP (''p''-OH-mCPP).<ref name="pmid9836023">{{cite journal |vauthors=Rotzinger S, Fang J, Coutts RT, Baker GB | title = Human CYP2D6 and metabolism of m-chlorophenylpiperazine | journal = Biological Psychiatry | volume = 44 | issue = 11 | pages = 1185–91 |date=December 1998 | pmid = 9836023 | doi = 10.1016/S0006-3223(97)00483-6| url = http://linkinghub.elsevier.com/retrieve/pii/S0006-3223(97)00483-6}}</ref><ref name="pmid21744514" /> Caution should be exercised in coprescribing [[CYP2D6#CYP2D6 ligands|inhibitors or substrates of CYP2D6]] with drugs such as [[trazodone]] and [[nefazodone]] that have mCPP as a metabolite.<ref name="pmid9836023" />

mCPP is a metabolite of a variety of other piperazine drugs including [[trazodone]], [[nefazodone]], [[etoperidone]], [[enpiprazole]], [[mepiprazole]], [[cloperidone]], and [[peraclopone]].<ref name="pmid21744514">{{cite journal | vauthors = Elliott S | title = Current awareness of piperazines: pharmacology and toxicology | journal = Drug Test Anal | volume = 3 | issue = 7-8 | pages = 430–8 | year = 2011 | pmid = 21744514 | doi = 10.1002/dta.307 | url = }}</ref>{{Additional citation needed|date=September 2017}} It is formed by [[dealkylation]] via [[CYP3A4]].<ref name="pmid21744514" /> mCPP may be responsible for some of their side effects.{{Citation needed|date=September 2017}}

==Chemistry==

===Analogues===
[[Structural analog|Analogue]]s of mCPP include:

* [[1-Benzylpiperazine]] (BZP)
* [[1-Methyl-4-benzylpiperazine]] (MBZP)
* [[1,4-Dibenzylpiperazine]] (DBZP)
* [[3-Trifluoromethylphenylpiperazine]] (TFMPP)
* [[3,4-Methylenedioxy-1-benzylpiperazine]] (MDBZP)
* [[4-Bromo-2,5-dimethoxy-1-benzylpiperazine]] (2C-B-BZP)
* [[pFPP|4-Fluorophenylpiperazine]] (pFPP)
* [[MeOPP|4-Methoxyphenylpiperazine]] (MeOPP)

Some additional analogues include [[quipazine]], [[ORG-12962]], and [[1-(3-chlorophenyl)-4-(2-phenylethyl)piperazine|3C-PEP]].

==Society and culture==
[[Image:MCPP tablets.jpg|thumb|right|200px|Tablets containing mCPP confiscated by the [[Drug Enforcement Administration|DEA]] in [[Vernon Hills, Illinois]].]]
[[Image:M-CPP Tablet 2008 -Kripo 2009 10 09.jpg|thumb|200px|right|Tablets containing mCPP confiscated by the [[Kriminalpolizei]] in [[Europe]] at the end of 2008.]]

===Legal status===

====Belgium====
mCPP is illegal in Belgium.<ref>[http://eldd.emcdda.europa.eu/html.cfm/index5176EN.html?sLanguageISO=EN&nNodeID=5176&pluginMethod=eldd.shownewsdetails&id=20/12/2006BELGIUM:%20New%20substances%20controlled%20include%20mCPP%20and%20khat EMCDDA]</ref>

====Brazil====
mCPP is illegal in [[Brazil]].<ref>[http://www.anvisa.gov.br/divulga/noticias/2008/051108_2.htm ANVISA resolution - Portaria SVS/MS 344/98]</ref>

====China====
As of October 2015 mCPP is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=China Food and Drug Administration | date=27 September 2015 | language=Chinese | accessdate=1 October 2015}}</ref>

====Czech Republic====
mCPP is legal in the Czech Republic.<ref>[http://www.mzcr.cz/Odbornik/obsah/legislativa_1051_3.html]</ref>

====Denmark====
mCPP is illegal in Denmark.<ref>[http://www.erowid.org/psychoactives/law/countries/denmark/denmark_law_info1.shtml Erowid.org]</ref>{{unreliable source?|date=May 2016}}

====Finland====
mCPP is illegal in [[Finland]].

====Germany====
mCPP is illegal in [[Germany]].

====Hungary====
mCPP is illegal in [[Hungary]] since 2012.

====Japan====
mCPP is illegal in [[Japan]] since 2006.

====Netherlands====
mCPP is legal in [[the Netherlands]].<ref>http://wetten.overheid.nl/BWBR0001941/2017-05-25#BijlageI</ref>

====New Zealand====
Based on the recommendation of the [[Expert Advisory Committee on Drugs|EACD]], the New Zealand government has passed legislation which placed BZP, along with the other piperazine derivatives TFMPP, mCPP, pFPP, MeOPP and MBZP, into Class C of the New Zealand Misuse of Drugs Act 1975. A ban was intended to come into effect in New Zealand on December 18, 2007, but the law change did not go through until the following year, and the sale of BZP and the other listed piperazines became illegal in New Zealand as of 1 April 2008. An amnesty for possession and usage of these drugs remained until October 2008, at which point they became completely illegal.<ref>[http://www.parliament.nz/en-NZ/PB/Legislation/Bills/d/3/d/00DBHOH_BILL8220_1-Misuse-of-Drugs-Classification-of-BZP-Amendment.htm Misuse of Drugs (Classification of BZP) Amendment Bill 2008]</ref> However, it is important to note that mCPP is legally used for scientific research.

====Norway====
mCPP is illegal in [[Norway]].

====Russia====
mCPP is illegal in [[Russia]].

====Sweden====
mCPP is illegal in [[Sweden]].

====Poland====
mCPP is illegal in [[Poland]].

====United States====
mCPP is not scheduled at the federal level in the [[United States]],<ref name="PART 1308 — SCHEDULES OF CONTROLLED SUBSTANCES - 1308.11 Schedule I">[http://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_11.htm 21 CFR — SCHEDULES OF CONTROLLED SUBSTANCES §1308.11 Schedule I.]</ref> but it is possible that it could be considered a controlled substance analog of [[benzylpiperazine|BZP]], in which case purchase, sale, or possession could be prosecuted under the [[Federal Analog Act]].

However, "chlorophenylpiperazine" is a Schedule I [[controlled substance]] in the state of [[Florida]] making it illegal to buy, sell, or possess in this state.<ref name="Florida Statutes - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL">[http://leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/0893.html Florida Statutes - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL]</ref>

==See also==
* [[Substituted piperazine]]

==References==
{{Reflist|2}}


{{Drug use}}
{{Monoamine releasing agents}}
{{Serotonin receptor modulators}}

{{DEFAULTSORT:Chlorophenylpiperazine, Meta-}}

[[Category:5-HT2A antagonists]]
[[Category:5-HT2B antagonists]]
[[Category:5-HT2C agonists]]
[[Category:Anxiogenics]]
[[Category:Chloroarenes]]
[[Category:Designer drugs]]
[[Category:Human drug metabolites]]
[[Category:Piperazines]]
[[Category:Serotonin receptor agonists]]
[[Category:Serotonin releasing agents]]
[[Category:Stimulants]]